Tech Company Financing Transactions

Euclises Pharmaceuticals Funding Round

On 4/8/2015, Euclises Pharmaceuticals secured $700 thousand in Series A investment from BioGenerator, Cultivation Capital and St. Louis Arch Angels.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

4320 Forest Park Ave. 304
St. Louis, MO 63108
USA

Phone

(314) 690-1441

Website

www.euclises.com

Email Address

Not Recorded

Overview

Euclises Pharmaceuticals, Inc. researches, develops, and commercializes medicines in the field of inflammation and oncology. Euclises Pharmaceuticals, Inc. was formerly known as Talley NewCo, Inc. The company was incorporated in 2011.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Bobby Sandage

        

Chief Financial Officer

Kathleen Beckmann

        

Chief Scientific Officer

John Talley

        

Browse more venture capital transactions:

Prev: 4/8/2015: Astro Twist venture capital transaction
Next: 4/8/2015: Admera Health venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary